Funder: Ipsen
Due Dates: Rolling (at least 90 days before event) | April 18, 2025 (Spasticity/Cervical Dystonia RFP) | November 13, 2026 (PBC RFP) | November 16, 2026 (Myelofibrosis RFP)
Funding Amounts: RFP contributions up to $300,000 each for PBC and myelofibrosis; up to $75,000 for the 2025 neuroscience RFP
Summary: Supports organizational fellowships, award programs, scholarships, and independent education aligned with rare disease, neuroscience, and oncology priorities.
Key Information: Fellowships, awards, and scholarships must be administered by nonprofits, teaching hospitals, or similar academic medical institutions.
Description
Ipsen considers funding for fellowships, award programs, and scholarships that further research in its therapeutic areas of focus. Its 2026 rare disease priorities are fibrodysplasia ossificans progressiva (FOP), primary biliary cholangitis (PBC), progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS), and biliary atresia. Neuroscience priorities include cervical dystonia and other dystonic disorders, spasticity, other movement disorders, and migraine. Oncology priorities are pancreatic cancer and myelofibrosis.
Ipsen also issues focused requests for proposals for independent medical education addressing unmet educational needs. Shared grant requirements emphasize balanced, accurate, non-misleading information for a broad audience and reasonable costs. Ipsen’s Grant Review Committee assesses scientific, medical, and/or public health criteria. Funding is not conditioned on purchasing, prescribing, recommending, or otherwise supporting Ipsen products, and creates no obligation to do so.
